Find a Clinical Trial

Showing 21 - 27 of 27 Trials

  • ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03919071

    Population:

    Pediatrics

    Phase:

    II
    The purpose of this study is to see if using two drugs called dabrafenib and trametinib after radiation treatment will be better than treatments used in the past in improving survival for patients with newly-diagnosed high grade glioma (HGG) that have the BRAF V600-mutation (a gene change within tumor cells). It is expected that the combination of these two medications that target the gene change and its cellular growth pathway will demonstrate clinical success when given as maintenance therapy following standard radiation therapy. Treatment on this study may last for approximately 2 years...

  • Head Start 4: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed By

    Principal Investigator:

    James Hinkley Garvin Jr, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02875314

    Population:

    Pediatrics

    Phase:

    IV
    This is a prospective randomized clinical trial, to determine whether dose- intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing Head Start 4 Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated...

  • A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors

    Principal Investigator:

    Fabio M. Iwamoto, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04478279

    Population:

    Adult

    Phase:

    I/II
    With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' Investigational means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18...

  • A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

    Principal Investigator:

    Susan E. Bates, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04068194

    Population:

    Adult

    Phase:

    I/II
    This study is being done to answer the following question: Is M3814 in combination with radiation therapy and avelumab safe and tolerable in patients with advanced or metastatic cancers. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced or metastatic cancer. The usual approach is defined as care most people get for advanced or metastatic solid tumor. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have a tumor which has spread to other parts of your body or that has advanced and...

  • Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04972110

    Population:

    Adult

    Phase:

    I/II
    The study is being done to learn how safe and effective the study drug, RP- 3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are design to stop cancer cells from growing. Are you Eligible? (Inclusion Criteria) Aged 18 years or older. Diagnosed with locally advanced or metastatic cancer. Have not received prior therapy with another...

  • A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04960787

    Population:

    Adult

    Phase:

    NA
    Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage the financial aspects of cancer care? A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health...

  • Trial of a Smartphone Application to Improve Medication Adherence among Patients with Cancer

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to learn about the difficulties patients have with the amount of medication they are required to take and to see if a smart phone application can make that process easier for patients. Patients will be asked to use an application on their smartphone or tablet daily and to come to the clinic once a month for 3 months. Are you Eligible? (Inclusion Criteria) Do you have advanced or metastatic cancer, or a hematologic malignancy? Are you taking, or planning to take at least one oral anti-cancer drug? Do you have access to a mobile phone or tablet that can download...

Pages